Many targeted drugs, such as those which target the ER, PI3K and MAPK signaling pathways, have been clinically approved based on evidence of clinical benefit and are being used to treat various cancer types (Massard et al., 2017; Dugger et al., 2018; Marquart et al., 2018; National Cancer Institute, 2021). This evidence concerns the gene PIK3CA and cancer.